Does the media prefer CTNM or PBH?

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 4 articles in the media. Contineum Therapeutics' average media sentiment score of 1.16 beat Prestige Consumer Healthcare's score of 1.06 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prestige Consumer Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTNM or URGN?

In the previous week, Urogen Pharma had 6 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Urogen Pharma and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Urogen Pharma's score of 0.69 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is CTNM or RAPP more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Rapport Therapeutics N/A -29.02% -27.37%

Does the media favor CTNM or RAPP?

In the previous week, Rapport Therapeutics had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 7 mentions for Rapport Therapeutics and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Rapport Therapeutics' score of 1.02 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CTNM or CMPS more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Compass Pathways N/A -49.63% -13.08%

Does the media prefer CTNM or CMPS?

In the previous week, Compass Pathways had 10 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for Compass Pathways and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Compass Pathways' score of 0.47 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRGO or CTNM?

In the previous week, Contineum Therapeutics had 2 more articles in the media than Perrigo. MarketBeat recorded 4 mentions for Contineum Therapeutics and 2 mentions for Perrigo. Contineum Therapeutics' average media sentiment score of 1.16 beat Perrigo's score of 0.55 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Contineum Therapeutics (CTNM) Competitors

$14.82 +0.16 (+1.09%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$14.81 -0.01 (-0.07%)

As of 09/11/2026 04:10 PM Eastern

Compare

CTNM vs. PBH, URGN, RAPP, CMPS, and PRGO

Should you buy Contineum Therapeutics stock or one of its competitors? Contineum Therapeutics's main competitors and comparable companies include Prestige Consumer Healthcare (PBH), Urogen Pharma (URGN), Rapport Therapeutics (RAPP), Compass Pathways (CMPS), and Perrigo (PRGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Contineum Therapeutics compare to Prestige Consumer Healthcare?

Contineum Therapeutics (NASDAQ:CTNM) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Contineum Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Contineum Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Contineum Therapeutics presently has a consensus target price of $20.25, suggesting a potential upside of 36.64%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 50.55%. Given Prestige Consumer Healthcare's higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

99.9% of Prestige Consumer Healthcare shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prestige Consumer Healthcare has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A
Prestige Consumer Healthcare	$1.10B	2.02	$190.30M	$3.57	13.16

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 4 articles in the media. Contineum Therapeutics' average media sentiment score of 1.16 beat Prestige Consumer Healthcare's score of 1.06 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prestige Consumer Healthcare beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to Urogen Pharma?

Contineum Therapeutics (NASDAQ:CTNM) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Contineum Therapeutics currently has a consensus target price of $20.25, suggesting a potential upside of 36.64%. Urogen Pharma has a consensus target price of $52.38, suggesting a potential upside of 23.79%. Given Contineum Therapeutics' higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Contineum Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Contineum Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Urogen Pharma	-51.73%	N/A	-43.79%

91.3% of Urogen Pharma shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A
Urogen Pharma	$109.79M	18.84	-$153.49M	-$1.98	N/A

In the previous week, Urogen Pharma had 6 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Urogen Pharma and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Urogen Pharma's score of 0.69 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Rapport Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Contineum Therapeutics' return on equity of -24.73% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Contineum Therapeutics presently has a consensus target price of $20.25, suggesting a potential upside of 36.64%. Rapport Therapeutics has a consensus target price of $62.86, suggesting a potential upside of 44.10%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Contineum Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Contineum Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Rapport Therapeutics had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 7 mentions for Rapport Therapeutics and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Rapport Therapeutics' score of 1.02 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics beats Rapport Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Contineum Therapeutics compare to Compass Pathways?

Contineum Therapeutics (NASDAQ:CTNM) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

46.2% of Compass Pathways shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Contineum Therapeutics has higher revenue and earnings than Compass Pathways. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Compass Pathways	N/A	-49.63%	-13.08%

Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

In the previous week, Compass Pathways had 10 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for Compass Pathways and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.16 beat Compass Pathways' score of 0.47 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics currently has a consensus target price of $20.25, suggesting a potential upside of 36.64%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 62.77%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Compass Pathways beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to Perrigo?

Perrigo (NYSE:PRGO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Contineum Therapeutics has lower revenue, but higher earnings than Perrigo. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.45	-$1.43B	-$12.51	N/A
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A

In the previous week, Contineum Therapeutics had 2 more articles in the media than Perrigo. MarketBeat recorded 4 mentions for Contineum Therapeutics and 2 mentions for Perrigo. Contineum Therapeutics' average media sentiment score of 1.16 beat Perrigo's score of 0.55 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 41.50%. Contineum Therapeutics has a consensus target price of $20.25, indicating a potential upside of 36.64%. Given Perrigo's higher possible upside, equities research analysts clearly believe Perrigo is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Contineum Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$557.54M	$12.44B	$7.17B	$12.85B
Dividend Yield	N/A	2.63%	2.57%	11.71%
P/E Ratio	-8.57	799.75	274.94	25.33
Price / Sales	11.15	960.75	685.45	111.12
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	2.12	10.39	10.33	6.20
Net Income	-$59.98M	$2.85B	$3.50B	$358.50M
7 Day Performance	-11.26%	-3.61%	-3.32%	-2.35%
1 Month Performance	-1.07%	0.86%	-0.41%	-2.77%
1 Year Performance	20.00%	3.47%	19.21%	7.63%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	1.9303 of 5 stars	$14.82 +1.1%	$20.25 +36.6%	+25.5%	$557.54M	$50M	N/A	31	News Coverage
PBH Prestige Consumer Healthcare	3.4198 of 5 stars	$48.96 -1.7%	$70.75 +44.5%	-27.8%	$2.32B	$1.09B	13.71	540	Positive News
URGN Urogen Pharma	2.9748 of 5 stars	$46.30 +5.7%	$50.38 +8.8%	+119.8%	$2.27B	$109.79M	N/A	200	Analyst Forecast Gap Up
RAPP Rapport Therapeutics	2.9432 of 5 stars	$44.24 -4.0%	$62.86 +42.1%	+88.0%	$2.12B	$20M	N/A	N/A	Positive News Insider Trade
CMPS Compass Pathways	2.4467 of 5 stars	$14.76 +5.1%	$23.36 +58.2%	+173.9%	$2.05B	N/A	N/A	120	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PBH, URGN, RAPP, CMPS, and PRGO

How does Contineum Therapeutics compare to Prestige Consumer Healthcare?

Summary

How does Contineum Therapeutics compare to Urogen Pharma?

Summary

How does Contineum Therapeutics compare to Rapport Therapeutics?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Summary

How does Contineum Therapeutics compare to Perrigo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PBH, URGN, RAPP, CMPS, and PRGO

How does Contineum Therapeutics compare to Prestige Consumer Healthcare?

Is CTNM or PBH more profitable?

Which has more volatility and risk, CTNM or PBH?

Do analysts recommend CTNM or PBH?

Do institutionals & insiders hold more shares of CTNM or PBH?

Which has stronger earnings & valuation, CTNM or PBH?

Does the media prefer CTNM or PBH?

Summary

How does Contineum Therapeutics compare to Urogen Pharma?

Do analysts recommend CTNM or URGN?

Which has more risk and volatility, CTNM or URGN?

Is CTNM or URGN more profitable?

Do institutionals & insiders hold more shares of CTNM or URGN?

Which has better earnings and valuation, CTNM or URGN?

Does the media refer more to CTNM or URGN?

Summary

How does Contineum Therapeutics compare to Rapport Therapeutics?

Is CTNM or RAPP more profitable?

Do analysts prefer CTNM or RAPP?

Which has more volatility & risk, CTNM or RAPP?

Which has preferable valuation and earnings, CTNM or RAPP?

Does the media favor CTNM or RAPP?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Do insiders and institutionals have more ownership in CTNM or CMPS?

Which has preferable valuation & earnings, CTNM or CMPS?

Is CTNM or CMPS more profitable?

Which has more risk & volatility, CTNM or CMPS?

Does the media prefer CTNM or CMPS?

Do analysts prefer CTNM or CMPS?

Summary

How does Contineum Therapeutics compare to Perrigo?

Do insiders & institutionals believe in PRGO or CTNM?

Is PRGO or CTNM more profitable?

Which has higher valuation and earnings, PRGO or CTNM?

Does the media favor PRGO or CTNM?

Which has more risk & volatility, PRGO or CTNM?

Do analysts recommend PRGO or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools